ARMATA PHARMACEUTICALS INC (ARMP)
Health Care · Bacteriophage therapeutics / anti-infective biotechnology · NYSE American
Armata is a clinical-stage phage biotech using engineered bacteriophages as a targeted, microbiome-friendly alternative to antibiotics for drug-resistant bacterial infections.
What ARMATA PHARMACEUTICALS INC does
Armata Pharmaceuticals is a late clinical-stage biotechnology company developing high-purity bacteriophage therapeutics to treat antibiotic-resistant and difficult-to-treat bacterial infections. The company has completed three Phase 2 clinical trials for its lead candidates AP-PA02 (targeting Pseudomonas aeruginosa) and AP-SA02 (targeting Staphylococcus aureus), leveraging its proprietary bacteriophage identification, characterization, and cGMP manufacturing capabilities. Bacteriophages represent a differentiated alternative to antibiotics that kill specific bacteria while preserving the healthy human microbiome, addressing the growing global threat of antibiotic resistance.
Themes: Antibiotic resistance / bacteriophage therapy, Cystic fibrosis, Non-cystic fibrosis bronchiectasis, Chronic pulmonary infections, Systemic bacterial infections, Alternative to broad-spectrum antibiotics, Microbiome-preserving therapeutics
Fundamentals
- Price$5.10 as of 2026-08-21 close
- Market cap$190M as of 2026-08-21
- 1-year return+109.9% 2025-08-21 close $2.43 → 2026-08-21 close $5.10
- P/En/a negative earnings
- Net margin-5432.8% as of 2026-08-24
- ROE-120.0% as of 2026-08-24
- Debt / equity1.38 as of 2026-08-24
- Revenue growth (YoY)+10.7% as of 2026-08-24
- Beta1.39 as of 2026-08-24
- Last reported earnings2026-08-12 SEC EDGAR Form 8-K (Item 2.02)
How ARMP compares in its sector
- net profit marginbottom 10% 504 covered Health Care peers, as of 2026-08-24
- operating marginbottom 25% 504 covered Health Care peers, as of 2026-08-24
- return on equitybottom 25% 576 covered Health Care peers, as of 2026-08-24
- free cash flow (absolute dollars, latest fiscal year)middle range 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Dividend coverage
Not assessed — last reported dividend predates the accounts. The most recent fiscal year in which ARMP reported a dividend payment is FY2016, while its reported financial statements run through FY2025. Coverage is therefore not assessed for the latest year — an FY2016 ratio would not describe ARMP today.
Coverage is derived from reported SEC EDGAR XBRL figures, comparing dividends paid against net income and free cash flow for the SAME fiscal year. It is not shown here because the latest fiscal year with a reported dividend payment (FY2016) is older than the latest year of reported financial statements (FY2025), so any ratio would describe an out-of-date year. Informational only — not financial advice.
How ARMATA PHARMACEUTICALS INC looks technically
ARMATA PHARMACEUTICALS INC (ARMP) is trading 32.4% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed below its 200-day average about 28 trading days ago — a "death cross", a bearish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 19, below the 25 that marks a real trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 53, neither overbought (above 70) nor oversold (below 30). It made a new 20-day low about 26 trading days ago. It is 68.8% below its highest point of the past year. Day-to-day price swings are unusually narrow versus its own recent history — a "Bollinger squeeze" (in the tightest 6% of the past ~6 months), which often precedes a bigger move.
Trend
8
| Distance from the 200-day | it is trading 32.4% below its 200-day average, the long-term trend line — a long-term downtrend | -32.4% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $5.40 | $5.40 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $7.55 | $7.55 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing low 9 calendar days ago — the swings before that are what the structure reading is measured on | 9 sessions |
| Wave structure | its recent swings can be read as a completed five-part downward sequence — the pattern Elliott-wave chartists call an impulse — which on that reading would now be due a pullback rather than more of the same; the labelling fails if price closes below 3.96. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible five-wave downward sequence, complete (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 28 trading days ago — a "death cross", a bearish long-term signal | 28 sessions |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 19, below the 25 that marks a real trend) | 19.2 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 53, neither overbought (above 70) nor oversold (below 30) | 52.6 |
|---|---|---|
| Position in its 14-day range | it is trading in the upper half of its 14-day range ($3.96 to $5.70) — its "stochastic" reading is 66 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 65.5 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in positive territory (momentum leaning bullish) | 24 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $16.34 | $16.34 |
|---|---|---|
| From the 52-week high | it is 68.8% below its 52-week high (its highest price of the past year) | -68.8% |
| Above the 52-week low | it is 112.5% above its 52-week low (its lowest price of the past year) | +112.5% |
| Below the 52-week high | it is 68.8% below its highest point of the past year | 68.8% |
| Since a 20-day breakout | it made a new 20-day low about 26 trading days ago | 26 sessions |
| Since a 55-day breakout | it made a new 55-day low about 26 trading days ago | 26 sessions |
| All-time high | its highest closing price on record is $1960000.00 (set on 2000-02-18) | $1960000.00 |
| Given back of the 52-week move | over the past year its closes ranged ($2.43 to $14.80), and it has given back well over two thirds of its rise from last year’s low — 78% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $6.76 to $7.16. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 78.4% |
| From the all-time high | it is 100.0% below its all-time high | -100.0% |
| Nearest price level | it is trading 11.4% below a resistance level at $5.68 — a price it turned at twice since 2026-01-15, most recently on 2026-08-04. Since 2024-08-21 it has 7 such levels below the current price and 2 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +11.4% |
| All-time low | its lowest closing price on record is $0.83 (set on 2022-12-28) | $0.83 |
| Above the all-time low | it is 514.5% above its all-time low | +514.5% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually narrow versus its own recent history — a "Bollinger squeeze" (in the tightest 6% of the past ~6 months), which often precedes a bigger move | 6th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.5685 between its high and its low — about 11.2% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.5685 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $4.20 and $5.18 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $4.20 – $4.69 – $5.18 |
| Typical daily range (% of price) | its price moves about 11.2% in a typical session — among the most volatile in the catalog. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 11.2% |
| Stretch from the 200-day average | it is trading 4.3 daily ranges below its 200-day average price (32.4% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 4.3 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.72× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | not available for this company yet | n/a |
Candlestick patterns
2
| Since a bullish engulfing | today it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | today |
|---|---|---|
| Since a bearish engulfing | 9 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 9 sessions ago |
Price gaps
2
| Gap at the open | it opened on 2026-08-21 at essentially the same price it closed at the session before — no meaningful overnight gap | 0.0% |
|---|---|---|
| Gap filled | a 4.5% gap up opened on 2026-08-10 has been "filled" 9 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 9 sessions ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 3.5 percentage points (the stock lost 1.2% while the market gained 2.3%) | -3.5% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 41.1 percentage points (the stock lost 38.0% while the market gained 3.1%) | -41.1% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 52.6 percentage points (the stock lost 41.6% while the market gained 11.1%) | -52.6% |
| vs market, 12 months | over the past 12 months this stock beat the market by 89.4 percentage points (the stock gained 109.9% while the market gained 20.5%) | +89.4% |
Signal agreement
2
| Bullish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bullish state: MACD momentum is positive — these describe past price behaviour, not a forecast | 1 of 9 |
|---|---|---|
| Bearish technical signals | 4 of the 9 technical signals we can compute for it are currently in a bearish state: a "death cross" — its 50-day average is below its 200-day, trading below its 200-day average, lagging the market over 6 months, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 4 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 7.3% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-15 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is thick, spanning 37.3% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | -7.3% |
|---|
Volume-weighted price
1
| Vs this year’s average price paid | the price is 28% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $7.10 — a volume-weighted average of daily closes over 159 sessions, not a true tick-by-tick VWAP. | -28.2% |
|---|
Price levels it has turned at before
ARMP last closed at $5.10 on 2026-08-21. Since 2024-08-21 it has turned at 7 prices below its last close and 2 above; the 3 nearest below and the 2 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $5.68 | Resistance | 11.4% above the last close | turned there twice · 2026-01-15 to 2026-08-04 |
| $7.43 | Resistance | 45.8% above the last close | turned there twice · 2025-11-20 to 2026-03-20 |
| $2.72 | Support | 46.7% below the last close | turned there three times · 2025-05-20 to 2025-08-19 |
| $2.39 | Support | 53.1% below the last close | turned there three times · 2024-11-27 to 2025-09-02 |
| $2.29 | Support | 55.0% below the last close | turned there four times · 2024-12-11 to 2025-03-21 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now complete.
This labelling fails — stops being a possible reading at all — if it closes below $3.96.
It is the only labelling that fits these swings, though its proportions are not the textbook ones. It was chosen from 4 labellings that survived the rules, counting shorter readings of the same bars.
This reading has stood for 3 trading days, since 2026-08-19.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Recent death cross (50-day crossed below 200-day) · Pulled back from the 12-month high · in a Bollinger Band volatility squeeze · trendless / choppy (low ADX) · lagging the market | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low · bollinger bands
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.00 mean, 1=Strong Buy…5=Strong Sell) — 2 analysts
- Mean price target$17.50 range $15.00 – $20.00
Analyst estimates, as of 2026-08-17. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Key risks (from latest filing)
["Clinical development and regulatory approval timelines are uncertain; company must successfully complete Phase 2b/Phase 3 trials and obtain FDA approval for any product commercialization.","Bacteriophage manufacturing at scale remains challenging; the company relies on its Los Angeles cGMP facility and third-party suppliers, with limited control over capacity and performance.","Company is unprofitable with significant accumulated losses and anticipated near-term operating losses; continued ability to raise capital is essential to fund ongoing clinical development."]
What changed in the latest 10-Q
AI-assisted comparison of ARMP's 10-Q filed 2026-05-13 against the prior one filed 2025-11-12.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing (2026-05-13) describes company as 'late clinical-stage biotechnology company' versus older filing's 'clinical-stage biotechnology company'
- Newer filing (2026-05-13) adds: 'and potency' to describe bacteriophage therapeutics focus
- Newer filing (2026-05-13) adds detailed section on manufacturing improvements: 'Importantly, we have improved our manufacturing processes, which significantly increases phage titers and purity, and improves production efficiency. Aligned with these improvements, we have been able to reproducibly produce high titer and high purity phages with lot-to-lot consistency, configuring our phage platform for full commercialization with the goal of ensuring commercial viability of our current and future phage product candidates across a variety of potential use cases.'
- Newer filing (2026-05-13) references Form 10-K for year ended December 31, 2025 filed March 25, 2026
- Older filing (2025-11-12) includes forward-looking statement: 'having resources sufficient to fund our operations into the first quarter of 2026' which is removed in newer filing
- Removed:
- Older filing (2025-11-12) describes engineered bacteriophages as 'engineered (synthetic)' - parenthetical clarification removed in newer filing (2026-05-13)
- Older filing (2025-11-12) references 'target pipeline' - changed to implicit reference in newer filing
- Older filing (2025-11-12) states 'Our optimized manufacturing processes significantly increase phage titers and improve production efficiency with the goal of ensuring commercial viability' - expanded and restructured in newer filing
- Older filing (2025-11-12) includes specific statement: 'To date, we have completed three critical Phase 2 trials, utilizing two distinct phage cocktails against two different bacterial pathogens with the potential to treat chronic pulmonary disease complicated by bacterial infection, as well as acute systemic bacterial infection. In October 2025, we announced positive results from our Phase 2a diSArm study evaluating our intravenous bacteriophage cocktail candidate AP-SA02 for the treatment of complicated SAB, which demonstrated statistically significant improvement in clinical response rates and favorable tolerability. We believe these results support advancing AP-SA02 into a pivotal Phase 3 trial.' - this section not present in newer filing excerpt
- Older filing (2025-11-12) references Form 10-K for year ended December 31, 2024 filed March 21, 2025
- Reworded:
- Description of phage therapeutics changed from 'high-purity' in older filing (2025-11-12) to 'high-purity and potency' in newer filing (2026-05-13)
- Description changed from 'leading developer of clinical-stage phage therapeutics of high purity' (older, 2025-11-12) to 'leading developer of clinical-stage phage therapeutics of high purity and potency' (newer, 2026-05-13)
- Manufacturing narrative restructured: older filing (2025-11-12) uses passive voice 'Our optimized manufacturing processes'; newer filing (2026-05-13) uses active voice 'we have improved our manufacturing processes' with expanded detail on consistency and commercialization
- Notes:
- Both filings are truncated at similar points in the AP-PA02 section; full extent of changes in later sections cannot be assessed
- The newer filing excerpt is incomplete at the end, cutting off mid-sentence
- References to Form 10-K dates differ due to different fiscal year-ends and filing dates between quarterly periods
Risk Factors
- Added:
- Added bullet point regarding 'our expected financial and operating performance' (newer filing, filed 2026-05-13)
- Added bullet point regarding 'the expected timing of additional clinical trials, including Phase 1, Phase 2, Phase 2b, Phase 3 or registrational clinical trials' (newer filing, filed 2026-05-13)
- Added bullet point regarding 'our ability to obtain and maintain adequate coverage, pricing and reimbursement from third-party payors and governments' (newer filing, filed 2026-05-13)
- Removed:
- Removed bullet point regarding 'the expected timing of additional clinical trials, including Phase 1b/Phase 2 or registrational clinical trials' (older filing, filed 2025-11-12)
- Reworded:
- Forward-looking statements reference updated from 'Annual Report on Form 10-K for the year ended December 31, 2024 (the "2024 Annual Report")' to 'Annual Report on Form 10-K for the year ended December 31, 2025 (the "2025 Annual Report")' (newer filing, filed 2026-05-13)
- Clinical trial phases description changed from 'Phase 1b/Phase 2' to 'Phase 1, Phase 2, Phase 2b, Phase 3' to provide more granular clinical development stage options (newer filing, filed 2026-05-13)
- Notes:
- The older filing text appears truncated at the end (cuts off mid-sentence with 'i'), limiting full comparison of concluding statements
- Table of Contents page numbers differ slightly between filings (Item 1A Risk Factors: page 38 in newer vs. page 39 in older), but this reflects document formatting changes rather than substantive content changes
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales are on record for ARMP — recent Form 4 activity was compensation-related (awards, option exercises, or tax withholding), not open-market buying or selling.
View full insider trading history → View SEC Form 3/4/5 filingsOnly open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
4 institutional 13F filers reported holding ARMP as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 4
- Reported shares held 154,368
- Reported value $1,580,727
reported quarterly holdings change (2025-12-31 → 2026-03-31): 1 new, 0 increased, 2 decreased, 1 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
ARMP had 856,363 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
ARMP had 2.30% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 4.98 days to cover at the same settlement.
- Reported short interest (shares) 856,363
- Short interest (% of shares outstanding) 2.30%
- Prior settlement (shares) 704,657
- Reported change 21.53%
- Days to cover (reported) 4.98
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Adaptive Phage Therapeutics
- Locus Biosciences
- Phico Therapeutics
- Intellia Therapeutics (NTLA)
- CRISPR Therapeutics (CRSP)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare ARMP vs…
Frequently asked questions
What does ARMATA PHARMACEUTICALS INC (ARMP) do?
Armata Pharmaceuticals is a late clinical-stage biotechnology company developing high-purity bacteriophage therapeutics to treat antibiotic-resistant and difficult-to-treat bacterial infections. The company has completed three Phase 2 clinical trials for its lead candidates AP-PA02 (targeting Pseudomonas aeruginosa) and AP-SA02 (targeting Staphylococcus aureus), leveraging its proprietary bacteriophage identification, characterization, and cGMP manufacturing capabilities.
What sector is ARMATA PHARMACEUTICALS INC (ARMP) in?
ARMATA PHARMACEUTICALS INC (ARMP) is classified in the Health Care sector. Its industry is Bacteriophage therapeutics / anti-infective biotechnology. It trades on NYSE American.
Who are ARMATA PHARMACEUTICALS INC's (ARMP) competitors?
Notable peers of ARMATA PHARMACEUTICALS INC (ARMP) include Adaptive Phage Therapeutics, Locus Biosciences, Phico Therapeutics, Intellia Therapeutics and CRISPR Therapeutics. This peer set is informational only — not financial advice.
Is ARMATA PHARMACEUTICALS INC (ARMP) overbought or oversold right now?
ARMATA PHARMACEUTICALS INC (ARMP) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 53, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on ARMP come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.